Latest news with #OjaswiRana
Yahoo
07-04-2025
- Health
- Yahoo
Philips Applauded by Frost & Sullivan for Improving Imaging Quality and Efficiency in Healthcare with Its CT 3500 Imaging Solution
Philips CT 3500, a scalable, adaptable, and durable imaging solution, improves efficiency and care quality, optimizes patient and user experience, and enhances clinical outcomes and operational efficiency. SAN ANTONIO, April 6, 2025 /CNW/ -- Frost & Sullivan recently assessed the AI-enabled CT systems industry and, based on its findings, recognizes Philips with the 2024 Asia-Pacific New Product Innovation Award. Over the last 130 years, the company has transformed from a manufacturer of affordable incandescent light bulbs into a global leader in health technology. Headquartered in Amsterdam, the company focuses on providing better care for more people through innovative solutions across the healthcare continuum, from healthy living and disease prevention to precision diagnosis, personalized treatment, and home care. Philips aims to improve 2.5 billion lives annually by 2030, including 400 million in underserved communities. The company drives value-based care through advanced diagnostic imaging, image-guided therapy, patient monitoring, and health informatics. Philips emphasizes sustainability, long-term partnerships, and patient outcomes, delivering devices that offer value over a 10-year or more life cycle. This strategy highlights Philips as a global leader in health technology, focusing on ethical practices, sustainable healthcare, and impactful innovation that enhances patient care. Philips CT 3500 addresses the operational challenges of healthcare facilities, especially those in regions with growing patient populations. Its design allows for higher patient throughput without demanding significant increases in power or space, enabling hospitals with limited resources to manage larger patient loads efficiently while maintaining high standards of care. The Philips CT 3500 includes automation features that can help improve workflow efficiency and assist in streamlining the scanning process Precise Position uses a camera to enhance the vertical patient orientation accuracy by 50% and reduces positioning time by up to 23% compared to manual operations.1 Precise Planning suggests the scan area and Exam Card based on patient anatomy, for enhanced efficiency in exam prep and inter-operator consistency. Additionally, Precise Intervention offers automated setup and guidance support for tissue biopsies and needle-based procedures, which can help streamline workflow efficiency. CT 3500 allows operators to achieve high-quality imaging, with AI-assisted tools helping to standardize results, regardless of the user's experience. This user-friendly design, combined with the robust performance of the CT system, helps healthcare providers deliver reliable, consistent care even under constrained conditions. Ojaswi Rana, best practices research analyst at Frost & Sullivan, observed, "Philips CT 3500 exemplifies the company's global leadership and commitment to addressing diverse healthcare challenges. The system's broad adoption across regions facing high patient volumes and logistical hurdles highlights its effectiveness and versatility. By emphasizing a unified brand identity and investing in advanced technologies like AI, Philips enhances its global presence and positions itself as a pioneer in scalable, sustainable healthcare solutions for the future." The Philips CT 3500, unlike traditional entry-level CT scanners, incorporates advanced technology from its premium models. High-quality components, such as image detection and tube technology, enable even entry-level devices to produce accurate and high-resolution imaging essential for precise diagnosis and treatment planning. The CT 3500 employs AI-based Precise Image reconstruction technology to provide superior image quality at low dose. This technology enhances low-contrast detectability by up to 60%, reduces noise by 85%, and lowers radiation dose by 80%.2 Additionally, it reconstructs all reference protocols in under one minute, supporting efficient operation even in the busiest radiology departments. The CT 3500 manages high patient volumes while reducing the risk of unplanned downtime. Proactive maintenance and regular component checks and replacements prevent disruptions and significant delays in care, especially in remote areas or those with heavy patient loads. As a result, it contributes to continuous operation, helps providers avoid backlogs, and keeps services running smoothly. Philips' commitment to innovation, robust feedback mechanisms, and emphasis on reliability underscore its leadership in delivering high-quality, sustainable healthcare solutions globally. "Philips employs a customer-focused strategy to guarantee that its products meet users' specific desires and requirements. The company tailored its CT 3500 to accommodate various healthcare environments by incorporating adaptable design elements and user-friendly features. This customization helps meet the unique demands of different medical settings, boosting overall user satisfaction. Moreover, Philips provides ongoing education and flexible support options to ensure that operators and medical staff stay updated with the latest practices, improving their ability to use the CT 3500 effectively and efficiently," added Rana. With its strong overall performance, Philips earns Frost & Sullivan's 2024 Asia-Pacific New Product Innovation Award in the AI-enabled CT systems industry. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion. Contact: Tarini SinghE: About Philips 1 Based on Philips in-house assessment by five clinical experts, comparing manual positioning versus Precise Position in 40 clinical cases using a human body phantom. 2In clinical practice, the use of Precise Image may reduce CT patient dose depending on the clinical task, patient size, and anatomical location. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Dose reduction assessments were performed using reference body protocols with 1.0 mm slices at the "Smoother" setting, and tested on the MITA CT IQ Phantom (CCT189, The Phantom Laboratory) assessing the 10 mm pin and compared to filtered-back projection. A range is seen across the four pins, using a channelized hoteling observer tool, that includes lower image noise by 85% and improved low-contrast detectability from 0% to 60% at 50% to 80% dose reduction. NPS curve shift is used to evaluate image appearance, as measured on a 20 cm water phantom in the center 50 mm x 50 mm region of interest, with an average shift of 6% or less. Data on file. View original content to download multimedia: SOURCE Frost & Sullivan View original content to download multimedia: Sign in to access your portfolio
Yahoo
13-02-2025
- Business
- Yahoo
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources. SAN ANTONIO, Feb. 13, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the biotechnology contract research organization (CRO) industry and, based on its findings, recognizes Southern Star Research with the 2024 Asia-Pacific Competitive Strategy Leadership Award. The company is a full-service CRO specializing in guiding sponsors through the intricate process of bringing new medical products to market. Southern Star is a vital intermediary between small biotech companies in North America and Europe and clinical trial sites in Australia. Starting with a team of three, the company successfully conducted its first clinical trial in the cardiovascular sector and has expanded into an international team of specialists managing studies across the globe. Southern Star offers comprehensive support for early-phase clinical trials, leveraging its extensive expertise and strong industry relationships for safe and efficient trial initiation. It also offers comprehensive clinical operations, expert biometrics, safety and medical monitoring, medical writing services, and later-phase clinical trials across the APAC region. Southern Star positions itself as a service provider and a trusted ally, focusing on personalized support rather than transactional relationships. This approach distinguishes it from larger CROs and pharma companies, which prioritize volume over individual client needs. The company leverages a combination of cost-effectiveness, high-quality outcomes, and reduced regulatory bureaucracy in Australia to deliver swift and effective solutions that allow biotech firms to bring their products to market more efficiently. Southern Star employs strategic partnerships and a focused approach for effective clinical trial management, particularly in later phases. Recognizing that biotech firms and small pharma companies often prefer a one-stop shop for their Phase 3 trials, the company collaborates with various laboratories. These strategic alliances enable Southern Star to act as a comprehensive outsourced solution for clients—a capability that enhances its attractiveness to biotechs seeking a streamlined study process as it gives them access to necessary lab services through a trusted partner. Ojaswi Rana, best practices research analyst at Frost & Sullivan, observed, "Southern Star's commitment to customer value chain compression expertly reduces trial complexity and accelerates time-to-market for new medical products. By offering seamless, integrated solutions across all phases of clinical trials, the company improves efficiency and ensures that sponsors meet regulatory demands while optimizing resources. This strategic approach shortens development timelines significantly, providing sponsors with a clear competitive advantage in bringing innovative therapies to market swiftly and cost-effectively." Southern Star's dedication to employing only local staff sets it apart from many competitors, a strategy critical for maximizing the Australian government's research and development (R&D) tax incentives. The company employs highly specialized statisticians and maintains close relationships with them, giving it an edge over competitors who often struggle to find and retain such talent. Ensuring that all necessary skills are sourced locally enables Southern Star to provide high-quality services while remaining compliant with government regulations regarding tax incentives. By setting itself apart in a competitive landscape, Southern Star achieves exceptional client satisfaction and positions itself as a vital ally in navigating the complexities of clinical trials and ultimately driving successful outcomes. It employs a proactive, relationship-driven approach that emphasizes trust and personal connection. Its pivotal differentiation element is the profound trust established between the company and its clients. "Southern Star minimizes bureaucratic hurdles, reduces the number of steps in the customer journey, and accelerates the timeline from trial initiation to results reporting. Furthermore, it strategically aligns its operations with transformative megatrends, such as the expedited regulatory changes prompted by the COVID-19 pandemic. This alignment positions the company to capitalize on new opportunities and improve operational efficiency, solidifying its status as a critical player in the dynamic biotech industry," added Ojaswi. With its strong overall performance, Southern Star earns Frost & Sullivan's 2024 Asia-Pacific Competitive Strategy Leadership Award in the biotech CRO industry. Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning, and customer satisfaction. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion. Contact: Tarini SinghE: About Southern Star Research Southern Star Research is a full-service Contract Research Organization (CRO) dedicated to navigating the complexities of bringing new medical products to market. With a legacy of excellence that began 14 years ago in Sydney, we have grown from a small, passionate team into a global network of experts committed to delivering high-quality services in medical writing, clinical monitoring, project management, biostatistics, data management, safety and medical monitoring, and quality assurance. Southern Star Research has been recognized for its outstanding contributions to the field, winning prestigious awards such as the Frost and Sullivan 2024 Asia-Pacific Competitive Strategy Leadership Award and being named as Great Place to Work in Australia in 2024. Our international team continues to deliver innovative clinical trial solutions across diverse therapeutic areas, ensuring the success of every study we manage. SOURCE Frost & Sullivan
